目的 探討司美格魯肽不良反應(yīng)的發(fā)生規(guī)律和臨床表現(xiàn)特點，為臨床安全、合理用藥提供參考。方法 檢索中國知網(wǎng)、萬方、維普、PubMed、Web of Science、Embase數(shù)據(jù)庫，收集司美格魯肽所致不良反應(yīng)案例報道，進行統(tǒng)計分析。結(jié)果 共納入文獻21篇，涉及患者27例，女性17例（62.96%），男性10例（37.04%），平均年齡（52.19±17.05）歲。司美格魯肽主要用于糖尿病和減重，不良反應(yīng)多發(fā)生在用藥2個月內(nèi)（19例，70.37%），主要累及胃腸系統(tǒng)、免疫系統(tǒng)、肝膽系統(tǒng)、腎臟及泌尿系統(tǒng)等。27例患者經(jīng)停藥和對癥治療后，25例好轉(zhuǎn)，2例無明顯改善。結(jié)論 臨床醫(yī)生、藥師應(yīng)加強對司美格魯肽相關(guān)不良反應(yīng)的認識和監(jiān)測，及時診斷與治療，確保用藥安全。

Objective To investigate the regularity and clinical characteristics of adverse drug reactions of semaglutide in order to provide reference for clinical medication. Methods Case reports of the adverse drug reactions induced by semaglutide were retrieved from the databases of CNKI, Wanfang, VIP, PubMed, Web of Science and Embase, etc. Results A total of 27 cases were reported in 21 papers, including 10 males (37.04%) and 17 females(62.96%). The mean age of the patients was (52.19 ±17.05) years old. Semaglutide was mainly used for diabetes mellitus and weight loss, and adverse drug reactions occurred mostly within 2 months (19 cases, 70.37%), mainly involving gastrointestinal system, immune system, hepatobiliary system, kidney and urinary system, etc. After drug withdrawal and symptomatic treatment, 25 patients improved and 2 patients had no obvious improvement. Conclusion It is necessary to strengthen the understanding and monitoring the adverse drug reactions induced by semaglutide, and timely perform diagnosis and treatment of the adverse drug reactions to ensure medication safety.

R977

廣東省中醫(yī)藥局科研項目（20222154）